Silo Pharma submits pre-IND to FDA for SPC-15 intranasal PTSD treatment

Silo Pharma, Inc.

SPC-15 is an intranasal prophylactic treatment for PTSD and stress-induced anxiety disorder.
Pre-clinical data showed effective, consistent exposure in a non-GLP small animal study completed Feb 2024.
Silo expects to finalize an exclusive worldwide license with Columbia University in H1 2024.
Next steps: PIND and GLP studies both slated to commence in H2 2024 before IND submission.
Only two FDA-approved PTSD drugs exist; SPC-15 aims to increase stress resilience in high-risk populations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.